Community Trust & Investment Co. boosted its holdings in CVS Health Corporation (NYSE:CVS - Free Report) by 14.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 265,953 shares of the pharmacy operator's stock after acquiring an additional 33,457 shares during the quarter. CVS Health accounts for about 1.2% of Community Trust & Investment Co.'s investment portfolio, making the stock its 29th biggest position. Community Trust & Investment Co.'s holdings in CVS Health were worth $18,018,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Hopwood Financial Services Inc. acquired a new position in CVS Health in the fourth quarter valued at about $29,000. McIlrath & Eck LLC boosted its position in CVS Health by 32.6% in the fourth quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock valued at $32,000 after buying an additional 174 shares in the last quarter. Financial Perspectives Inc boosted its position in CVS Health by 137.5% in the fourth quarter. Financial Perspectives Inc now owns 805 shares of the pharmacy operator's stock valued at $36,000 after buying an additional 466 shares in the last quarter. Compass Planning Associates Inc acquired a new position in CVS Health in the fourth quarter valued at about $37,000. Finally, Providence First Trust Co acquired a new position in CVS Health in the fourth quarter valued at about $42,000. Institutional investors own 80.66% of the company's stock.
Analyst Upgrades and Downgrades
A number of equities analysts have recently issued reports on the stock. Wells Fargo & Company reiterated an "overweight" rating and set a $84.00 target price (up from $76.00) on shares of CVS Health in a research report on Tuesday, May 6th. Truist Financial upped their target price on shares of CVS Health from $82.00 to $84.00 and gave the stock a "buy" rating in a research report on Monday, May 12th. Cowen reiterated a "buy" rating on shares of CVS Health in a research report on Monday, May 5th. Barclays set a $79.00 target price on shares of CVS Health and gave the stock an "overweight" rating in a research report on Monday, June 2nd. Finally, UBS Group upped their target price on shares of CVS Health from $67.00 to $71.00 and gave the stock a "neutral" rating in a research report on Friday, May 2nd. Two research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $74.75.
View Our Latest Analysis on CVS Health
Insider Transactions at CVS Health
In other CVS Health news, Director Guy P. Sansone bought 1,570 shares of the firm's stock in a transaction that occurred on Thursday, June 5th. The stock was acquired at an average price of $63.70 per share, with a total value of $100,009.00. Following the completion of the transaction, the director now owns 12,007 shares in the company, valued at approximately $764,845.90. This trade represents a 15.04% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.22% of the stock is owned by insiders.
CVS Health Trading Down 0.3%
NYSE:CVS traded down $0.19 during trading hours on Thursday, hitting $66.91. The stock had a trading volume of 5,208,935 shares, compared to its average volume of 10,943,569. CVS Health Corporation has a one year low of $43.56 and a one year high of $72.51. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.63 and a current ratio of 0.82. The company has a market cap of $84.64 billion, a price-to-earnings ratio of 15.97, a P/E/G ratio of 0.96 and a beta of 0.56. The business's 50 day moving average is $65.02 and its 200-day moving average is $60.30.
CVS Health (NYSE:CVS - Get Free Report) last issued its earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, beating the consensus estimate of $1.62 by $0.63. CVS Health had a net margin of 1.39% and a return on equity of 10.59%. The firm had revenue of $94.59 billion during the quarter, compared to the consensus estimate of $93.07 billion. During the same quarter in the prior year, the firm earned $1.31 earnings per share. The business's quarterly revenue was up 7.0% on a year-over-year basis. Sell-side analysts anticipate that CVS Health Corporation will post 5.89 EPS for the current fiscal year.
CVS Health Profile
(
Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Featured Articles
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
